Found 4 articles for: "Brodalumab"
Mechanism of Action of Brodalumab May Correlate With Efficacy in Patients With Inflammatory Skin Diseases
October 2023 | Volume 22 | Issue 10 | Original Article | 994 | Copyright © October 2023
Biologic therapy is used for systemic treatment of multiple inflammatory conditions, including moderate-to-severe plaque psoriasis. Brodalumab is an interleukin-17 (IL-17) receptor A antagonist indica...
Read MoreBrodalumab: 4-Year US Pharmacovigilance Report
April 2023 | Volume 22 | Issue 4 | Features | 419 | Copyright © April 2023
Brodalumab is an interleukin-17 receptor A antagonist approved for the treatment of moderate-to-severe psoriasis in adults without response or with loss of response to other systemic therapies. B...
Read MoreLong-Term Skin Clearance With Brodalumab in Patients With Psoriasis and Inadequate Response to Prior Biologics
April 2022 | Volume 21 | Issue 4 | Original Article | 364 | Copyright © April 2022
Background: Despite the emergence of multiple biologic drug options for psoriasis, unmet treatment needs remain. Biologic therapies can vary in their effectiveness and adverse events,...
Read MoreOne-Year Pharmacovigilance Update of Brodalumab
August 2020 | Volume 19 | Issue 8 | Editorials | 807 | Copyright © August 2020
